Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Total 13F shares
-
76,868,092
-
Share change
-
-1,939,123
-
Total reported value
-
$738,604,939
-
Price per share
-
$9.61
-
Number of holders
-
164
-
Value change
-
-$15,160,885
-
Number of buys
-
82
-
Number of sells
-
80
Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q3 2022
As of 30 Sep 2022,
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) was held by
164 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
76,868,092 shares.
The largest 10 holders included
BlackRock Inc., Temasek Holdings (Private) Ltd, JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., VANGUARD GROUP INC, STATE STREET CORP, Kohlberg Kravis Roberts & Co. L.P., Aristotle Capital Boston, LLC, AMERIPRISE FINANCIAL INC, and PERCEPTIVE ADVISORS LLC.
This page lists
165
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.